Welcome to GSK’s product website

Here you will find information about GSK’s medicines and vaccines

I’m a UK healthcare professional

Important notice: this site is intended for UK healthcare professionals. By entering this site, you are confirming that you are a UK healthcare professional. This site may contain promotional information.

I’m a member of the UK public

This site is intended for members of the UK public, patients and their carers.

S.S. November 2020. PM-GB-NA-WCNT-200006

What is severe asthma?

Asthma which requires the use of high dose inhaled corticosteroids (ICS) plus a second controller
(and/or systemic corticosteroids) to prevent it from becoming ‘uncontrolled’ or which remains
‘uncontrolled’ despite this therapy.
[1] (International European Respiratory Society [ERS] and American Thoracic Society [ATS] Task Force.)

REFRACTORY DISEASE

Patients with refractory disease either remain uncontrolled despite their treatment being optimised or require high doses of controller and reliever medication to maintain control.[2]

EOSINOPHILIC PHENOTYPE

The eosinophilic asthma phenotype has been shown to be associated with asthma severity, late-onset disease and steroid refractoriness.[3]

TARGETED THERAPIES

By characterising a patient’s severe asthma phenotype, they can be treated differently with personalised and targeted therapies, and outcomes could be improved.[4]

Nucala is the first anti-IL-5 treatment that specifically targets the eosinophilic phenotype.[1],[5]

Prevalence and burden

Severe asthma patients are at high risk of having a severe exacerbation and are often dependent on oral corticosteroids.[7],[8]

These patients account for 50% of healthcare resource utilisation and have few therapeutic options available.[9],[10],[11]

Nucala is the first anti-IL-5 treatment that specifically targets the eosinophilic phenotype.[7],[12]

References:

  1. Chung KF, Wenzel SE, Brozek JL et al. Eur Respir J 2014;43:343–373.
  2. Moore WC, Bleecker ER, Curran-Everett D, et al. J Allergy Clin Immunol 2007;119:405–413.
  3. Hoskins G, McCowan C, Neville RG. et al. Thorax 2000;55:19–24.
  4. Campo P, Rodriguez F, Sánchez-García et al. J Investig Allergol Clin Immunol 2013;23:76–88.
  5. Peters S P, Ferguson G, Deniz Y et al. Respir med 2006;100:1139–1151.
  6. Nucala Summary of Product Characteristics.
  7. Chung KF, Wenzel SE, Brozek JL, et al. Eur Respir J 2014;43:343–373.
  8. Peters SP, Ferguson G, Deniz Y, et al. Respir Med 2006;100:1139–1151.
  9. Walford H, Doherty T. J Asthma Allergy 2014;11:53–65.
  10. Campo P, Rodriguez F, Sanchez-Garcia S, et al. J lnvestig Allergol Clin lmmunol 2013;23:76–88.
  11. Nucala Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Nucala is a registered trademark of the GlaxoSmithKline group of companies

PM-GB-MPL-WCNT-200003 v2.0 October 2020